All Posts Tagged With: "OSIR"
(ASTM) Aastrom Biosciences Analyst Initiates Coverage at Neutral
We are initiating coverage of Aastrom Biosciences (ASTM) with a Neutral rating and $2.50 price target. Aastrom is pioneering the research effort on adult stem cells for therapeutic applications, specifically...
(OSIR) Osiris Therapeutics Misses Estimates
Osiris Therapeutics (OSIR) reported a net loss of a cent in the fourth quarter of 2009, well below the Zacks Consensus Estimate of a net income of 23 cents per share. However, net loss in the year ago period...
(OSIR) Osiris Therapeutics Posts Loss
Osiris Therapeutics (OSIR) reported a net loss of 21 cents per share in the third quarter of 2009, well above the Zacks Consensus Estimate of a net income of 6 cents. However, net loss in the year ago period...
(OSIR) Osiris Therapeutics’ Prochymal Found Ineffective
We are disappointed with the failure of Osiris Therapeutics’ (OSIR) Prochymal, a drug derived from human stem cell for the treatment of graft-versus-host disease (GvHD), the most common complication of bone marrow transplants. Currently, there is no approved...